Anna WesoÅ‚owska

List of Publications by Year
in descending order

104	2,535	201385 27	233125 45
papers	citations	h-index	g-index

105	105	105	2117
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology, 2006, 51, 578-586.	2.0	200
2	Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology, 2007, 52, 1274-1283.	2.0	136
3	Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacological Reports, 2010, 62, 564-577.	1.5	106
4	Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. European Journal of Pharmacology, 2007, 555, 43-47.	1.7	95
5	Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. European Journal of Pharmacology, 2006, 553, 185-190.	1.7	93
6	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. European Journal of Medicinal Chemistry, 2013, 60, 42-50.	2.6	81
7	Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT₆ Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 972-983.	1.7	64
8	Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behavioural Pharmacology, 2007, 18, 439-446.	0.8	62
9	Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptorâ€”5-HT1A/5-HT2A/5-HT7 and D2/D3/D4â€”agents: The synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry, 2012, 20, 1545-1556.	1.4	59
10	Novel Arylsulfonamide Derivatives with 5-HT₆/5-HT₇ Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia. Journal of Medicinal Chemistry, 2014, 57, 4543-4557.	2.9	58
11	Activity of Serotonin 5-HT1A Receptor Biased Agonists in Rat: Anxiolytic and Antidepressant-like properties. ACS Chemical Neuroscience, 2018, 9, 1040-1050.	1.7	47
12	Influence of serotonin 5-HT(7) receptor blockade on the behavioral and neurochemical effects of imipramine in rats. Pharmacological Reports, 2008, 60, 464-74.	1.5	47
13	The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. Psychopharmacology, 2011, 217, 411-418.	1.5	43
14	The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment. International Journal of Molecular Sciences, 2019, 20, 3420.	1.8	43
15	Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. European Journal of Medicinal Chemistry, 2010, 45, 1295-1303.	2.6	42
16	N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. ACS Medicinal Chemistry Letters, 2016, 7, 618-622.	1.3	42
17	In the search for a lead structure among series of potent and selective hydantoin 5â€<scp>HT</scp>₇R agents: The drugâ€likeness in vitro study. Chemical Biology and Drug Design, 2017, 90, 1295-1306.	1.5	41
18	Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT1A and 5-HT7 Antagonists in Animal Models. PLoS ONE, 2015, 10, e0142499.	1.1	39

#	Article	IF	Citations
19	MF-8, a novel promising arylpiperazine-hydantoin based 5-HT 7 receptor antagonist: In vitro drug-likeness studies and in vivo pharmacological evaluation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 878-883.	1.0	36
20	On the Bioactive Conformation of NAN-190 (1) and MP3022 (2), 5-HT1AReceptor Antagonistsâ€. Journal of Medicinal Chemistry, 1999, 42, 4952-4960.	2.9	35
21	Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands. Bioorganic and Medicinal Chemistry, 2011, 19, 6750-6759.	1.4	33
22	The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine. European Journal of Medicinal Chemistry, 2017, 135, 117-124.	2.6	33
23	Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 545-557.	1.4	32
24	Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent. Bioorganic and Medicinal Chemistry, 2015, 23, 3436-3447.	1.4	32
25	Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease. Cardiovascular & Hematological Disorders Drug Targets, 2014, 14, 34-44.	0.2	31
26	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile. Bioorganic and Medicinal Chemistry, 2015, 23, 212-221.	1.4	31
27	Towards new 5-HT 7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties. European Journal of Medicinal Chemistry, 2016, 108, 334-346.	2.6	28
28	Active conformation of some arylpiperazine postsynaptic 5-HT1A receptor antagonists. European Journal of Medicinal Chemistry, 2002, 37, 273-283.	2.6	27
29	The selective 5-HT6 receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats. European Journal of Pharmacology, 2008, 582, 88-93.	1.7	27
30	Structureâ€“activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity. European Journal of Medicinal Chemistry, 2015, 97, 142-154.	2.6	27
31	Design, synthesis, and biological evaluation of fluorinated imidazo[1,2- a]pyridine derivatives with potential antipsychotic activity. European Journal of Medicinal Chemistry, 2016, 124, 456-467.	2.6	27
32	5-HT6 receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801. Brain Research, 2019, 1722, 146375.	1.1	27
33	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. European Journal of Medicinal Chemistry, 2015, 92, 221-235.	2.6	26
34	Study into a possible mechanism responsible for the antidepressant-like activity of the selective 5-HT6 receptor antagonist SB-399885 in rats. Pharmacological Reports, 2007, 59, 664-71.	1.5	26
35	The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: The impact of benzodiazepine receptors. European Journal of Pharmacology, 2008, 580, 355-360.	1.7	25
36	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. Journal of Medicinal Chemistry, 2017, 60, 7483-7501.	2.9	25

#	Article	IF	Citations
37	The impact of the halogen bonding on D 2 and 5-HT 1A /5-HT 7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. Bioorganic and Medicinal Chemistry, 2017, 25, 3638-3648.	1.4	24
38	Synthesis and biological evaluation of 2-fluoro and 3-trifluoromethyl-phenyl-piperazinylalkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione as potential antidepressant agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 10-24.	2.5	21
39	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT_{1A} Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry, 2019, 62, 2750-2771.	2.9	21
40	Anticonvulsant effect of the selective 5-HT1B receptor agonist CP 94253 in mice. European Journal of Pharmacology, 2006, 541, 57-63.	1.7	19
41	Pharmacological characterization of MP349, a novel 5-HT1A-receptor antagonist with anxiolytic-like activity, in mice and rats. Journal of Pharmacy and Pharmacology, 2010, 55, 533-543.	1.2	19
42	The influence of substitution at aromatic part of 1,2,3,4-tetrahydroisoquinoline on in vitro and in vivo 5-HT1A/5-HT2A receptor activities of its 1-adamantoyloaminoalkyl derivatives. Bioorganic and Medicinal Chemistry, 2002, 10, 87-95.	1.4	18
43	Involvement of presynaptic 5-HT1A and benzodiazepine receptors in the anticonflict activity of 5-HT1A receptor antagonists. European Journal of Pharmacology, 2003, 471, 27-34.	1.7	18
44	Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. Neuropharmacology, 2014, 85, 253-262.	2.0	18
45	Novel 5-HT 7 R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile. Bioorganic and Medicinal Chemistry, 2017, 25, 2789-2799.	1.4	18
46	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules, 2018, 23, 2529.	1.7	18
47	Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6. European Journal of Medicinal Chemistry, 2019, 178, 740-751.	2.6	18
48	Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro. Molecules, 2019, 24, 4472.	1.7	18
49	Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacological Reports, 2013, 65, 998-1005.	1.5	17
50	Synthesis and 5-HT1A, 5-HT2A receptor activity of new Î²-tetralonohydantoins. European Journal of Medicinal Chemistry, 2005, 40, 820-829.	2.6	16
51	Towards novel 5-HT7 versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: Design, synthesis, and antidepressant properties. Part II. European Journal of Medicinal Chemistry, 2015, 92, 202-211.	2.6	16
52	Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1079-1088.	1.4	16
53	Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 839-849.	1.4	16
54	N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT7 receptor selectivity versus multireceptor profile. Bioorganic and Medicinal Chemistry, 2016, 24, 130-139.	1.4	16

#	Article	IF	Citations
55	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT 7 receptor agents with antidepressant activity. European Journal of Medicinal Chemistry, 2018, 147, 102-114.	2.6	16
56	S(+)- and R(â^')N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) as discriminative stimuli: Effect of cocaine. Pharmacology Biochemistry and Behavior, 2005, 82, 531-538.	1.3	15
57	New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation. Pharmacological Reports, 2013, 65, 15-29.	1.5	15
58	Novel Mannich Bases, 5â€Arylimidazolidineâ€2,4â€dione Derivatives with Dual 5â€HT_{1A} Receptor and Serotonin Transporter Affinity. Archiv Der Pharmazie, 2013, 346, 98-109.	2.1	15
59	3-Aminomethyl Derivatives of 2-Phenylimidazo[1,2-a]-pyridine as Positive Allosteric Modulators of GABA_A Receptor with Potential Antipsychotic Activity. ACS Chemical Neuroscience, 2017, 8, 1291-1298.	1.7	15
60	Discovery of Novel pERK1/2- or Î²-Arrestin-Preferring 5-HT_{1A} Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. Journal of Medicinal Chemistry, 2020, 63, 10946-10971.	2.9	15
61	Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties inÂvivo. European Journal of Medicinal Chemistry, 2020, 203, 112529.	2.6	14
62	Arylsulfonamide derivatives of (aryloxy)ethylpiperidines as selective 5-HT₇ receptor antagonists and their psychotropic properties. MedChemComm, 2015, 6, 1272-1277.	3.5	13
63	The preclinical discovery and development of cariprazine for the treatment of schizophrenia. Expert Opinion on Drug Discovery, 2018, 13, 779-790.	2.5	13
64	Behavioral Pharmacology: Potential Antidepressant and Anxiolytic Properties. International Review of Neurobiology, 2011, 96, 49-71.	0.9	12
65	The preclinical discovery and development of paliperidone for the treatment of schizophrenia. Expert Opinion on Drug Discovery, 2020, 15, 279-292.	2.5	12
66	ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 593-602.	1.4	11
67	The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases. International Journal of Molecular Sciences, 2021, 22, 10773.	1.8	11
68	New 7-arylpiperazinylalkyl-8-morpholin-4-yl-purine-2,6-dione derivatives with anxiolytic activity â€“ Synthesis, crystal structure and structureâ€“activity study. Journal of Molecular Structure, 2014, 1067, 243-251.	1.8	10
69	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1048-1062.	2.5	10
70	Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2020, 27, 5351-5373.	1.2	10
71	In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. Polish Journal of Pharmacology, 2002, 54, 327-41.	0.3	10
72	Aminoalkyl Derivatives of 8â€Alkoxypurineâ€2,6â€diones: Multifunctional 5â€HT_{1A}/5â€HT₇ Receptor Ligands and PDE Inhibitors with Antidepressant Activity. Archiv Der Pharmazie, 2016, 349, 889-903.	2.1	9

#	Article	IF	Citations
73	Antinociception: Mechanistic studies on the action of MD-354 and clonidine. Part 1. The 5-HT3 component. European Journal of Pharmacology, 2005, 528, 59-64.	1.7	8
74	Tail suspension test does not detect antidepressant-like properties of atypical antipsychotics. Behavioural Pharmacology, 2011, 22, 7-13.	0.8	8
75	Synthesis and biological investigation of new equatorial (Î²) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile. Bioorganic and Medicinal Chemistry, 2016, 24, 3994-4007.	1.4	8
76	Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability. Bioorganic and Medicinal Chemistry, 2019, 27, 4163-4173.	1.4	8
77	Characteristics of metabolic stability and the cell permeability of 2â€pyrimidinylâ€piperazinylâ€alkyl derivatives of 1Hâ€imidazo[2,1 â€f]purineâ€2,4(3 H ,8 H)â€dione with antidepressantâ€and anxiolyticâ€like activities. Chemical Biology and Drug Design, 2019, 93, 511-521.	1.5	8
78	An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential. Bioorganic Chemistry, 2022, 121, 105695.	2.0	8
79	Modification of the Structure of 4, 6-Disubstituted 2-(4-Alkyl-1-piperazinyl)pyridines: Synthesis and Their 5-HT2A Receptor Activity. Archiv Der Pharmazie, 2003, 336, 104-110.	2.1	7
80	Synthesis and Pharmacological Evaluation of Novel Tricyclic[2,1â€f]theophylline Derivatives. Archiv Der Pharmazie, 2013, 346, 832-839.	2.1	7
81	Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders. Journal of Pharmacy and Pharmacology, 2014, 66, 1755-1762.	1.2	7
82	Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 37-49.	1.4	7
83	Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists. PLoS ONE, 2020, 15, e0237196.	1.1	7
84	Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. Current Medicinal Chemistry, 2019, 26, 4885-4913.	1.2	7
85	New Arylpiperazinylalkyl Derivatives of 8â€Alkoxyâ€purineâ€2,6â€dione and Dihydro[1,3]oxazolo[2,3â€f]purinedione Targeting the Serotonin 5â€HT_{1A}/5â€HT_{2A}/5â€HT₇ and Dopamine D₂ Receptors. Archiv Der Pharmazie, 2015, 348, 242-253.	2.1	6
86	Novel antagonists of 5-HT6 and/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats. Behavioural Brain Research, 2019, 359, 9-16.	1.2	6
87	Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives. Molecules, 2020, 25, 3868.	1.7	6
88	Effect of 5-HT6 Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2105-2127.	1.0	6
89	Diabetic Theory in Anti-Alzheimerâ€™s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents. Current Medicinal Chemistry, 2020, 27, 6658-6681.	1.2	6
90	Chronic antidepressant-like effect of EMD386088, a partial 5-HT6 receptor agonist, in olfactory bulbectomy model may be connected with BDNF and/or CREB signalling pathway. Pharmacological Reports, 2018, 70, 1047-1056.	1.5	5

#	Article	IF	Citations
91	Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. Journal of Medicinal Chemistry, 2021, 64, 12603-12629.	2.9	5
92	MD-354 selectively antagonizes the antinociceptive effects of (â^')nicotine in the mouse tail-flick assay. Psychopharmacology, 2010, 210, 547-557.	1.5	4
93	Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). European Journal of Medicinal Chemistry, 2020, 191, 112149.	2.6	4
94	Non-surgical methods for delaying skin aging processes.. Farmacja Polska, 2020, 76, 110-117.	0.1	4
95	Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. European Journal of Medicinal Chemistry, 2022, 233, 114218.	2.6	4
96	Structureâ€“5â€HT/D₂ Receptor Affinity Relationship in a New Group of 1â€Arylpiperazynylalkyl Derivatives of 8â€Dialkylaminoâ€3,7â€dimethylâ€1Hâ€purineâ€2,6(3H,7H)â€dione. Archiv Der Pharmazie, 2016, 349, 774-784.	2.1	2
97	Synthesis and biological investigations of 3Î²-aminotropane arylamide derivatives with atypical antipsychotic profile. Medicinal Chemistry Research, 2018, 27, 1906-1928.	1.1	2
98	The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and Î²-arrestin signalling. Journal of Psychopharmacology, 2020, 34, 1431-1442.	2.0	2
99	Pharmacological analysis of the hypothermic effects of NAN-190 and its analogs, postsynaptic 5-HT1A receptor antagonists, in mice. Polish Journal of Pharmacology, 2002, 54, 391-9.	0.3	1
100	Therapeutic monitoring of valproic acid - benefits and problems. Farmacja Polska, 2021, 77, 241-250.	0.1	0
101	Scalp needle mesotherapy as a method supporting the treatment of alopecia. Farmacja Polska, 2021, 77, 360-371.	0.1	0
102	CHANGES IN PHARMACOKINETIC PROPERTIES OF ANTIBACTERIAL DRUGS IN CRITICALLY ILL PATIENTS. Farmacja Polska, 2020, 76, 33-46.	0.1	0
103	Comparative analysis of valproic acid concentrations in terms of dosing and clinical effect monitoring in different age patients with diagnosed epilepsy. Farmacja Polska, 2022, 78, 111-122.	0.1	0
104	The selective 5-HT1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. Behavioural Pharmacology, 0, Publish Ahead of Print, .	0.8	0